Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 5/20 | 0.42 |
| ▸ | NPC1 | O15118 | 2/20 | 0.42 |
| ▸ | RAB9A | P51151 | 2/20 | 0.42 |
| ▸ | FKBP5 | Q13451 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 4/20 | 0.39 |
| ▸ | MAPT | P10636 | 4/20 | 0.39 |
| ▸ | LMNA | P02545 | 3/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.38 |
| ▸ | RORC | P51449 | 1/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | KCNK9 | Q9NPC2 | 2/20 | 0.37 |
| ▸ | TP53 | P04637 | 1/20 | 0.37 |
| ▸ | KCNK3 | O14649 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | MAOB | P27338 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14278014 | 0.87 | KMT2A (0.44) | KMT2ANPC1RAB9AFKBP5MEN1 | |
| SCHEMBL14364309 | 0.84 | CA1 (0.41) | KMT2AMEN1MAPTLMNASMN1; SMN2 | |
| SCHEMBL14278310 | 0.84 | KMT2A (0.42) | KMT2ANPC1RAB9AFKBP5MEN1 | |
| SCHEMBL14364310 | 0.80 | RAB9A (0.45) | KMT2ANPC1RAB9AMEN1ALDH1A1 | |
| SCHEMBL14364486 | 0.78 | KMT2A (0.44) | KMT2AMAPTLMNASMN1; SMN2POLB | |
| SCHEMBL14364314 | 0.76 | P2RX4 (0.32) | KMT2AMEN1 | |
| SCHEMBL14364343 | 0.75 | ALDH1A1 (0.48) | KMT2AMAPTLMNASMN1; SMN2POLB | |
| SCHEMBL14364337 | 0.75 | SLC40A1 (0.39) | KMT2ALMNASMN1; SMN2POLBALDH1A1 | |
| SCHEMBL14364348 | 0.75 | METAP2 (0.35) | KMT2ALMNA | |
| SCHEMBL14364350 | 0.74 | HTR6 (0.38) | KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070265281-A1 | Organic Compounds and Their Uses | COTTENS SYLVAIN | 2007-11-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070265281-A1 | Organic Compounds and Their Uses | OAT, OTC, AOX1 | KMT2A 3407/4885NPC1 177/4885RAB9A 4474/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.